Clin2
NCT06644755Possibly a fitRecruiting

First-in-human study of DS-2243a for advanced cancers

Solid TumorsSarcoma

Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.

This trial tests a new drug called DS-2243a for people with advanced solid tumors that have stopped responding to standard treatments. It targets a specific protein found in some cancers, and you need to have a particular immune system marker for it to work.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1
Enrollment
150 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You are 18 years or older.
  • You have one of these cancers that has spread or cannot be removed: synovial sarcoma, myxoid/round cell liposarcoma, non-small cell lung cancer, or urothelial cancer.
  • You have a specific immune marker called HLA-A*02 (a blood test can tell).
  • You have tried at least one standard treatment for your cancer, and it either didn't work or caused side effects.
  • You have a tumor that can be measured on a CT scan or MRI.
  • You are in generally good health (able to do daily activities) and your organs are working well enough.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07159126Recruiting· Phase 1
Study of DS3610a for advanced solid tumors

This trial tests a new drug called DS3610a for people with advanced solid tumors that have stopped responding to other treatments. You may be able to join if you have tried standard therapies and are willing to provide a tumor sample.

Chūōku
NCT07681882Recruiting· Phase 1
Testing DS1025a in people with advanced solid tumors

This trial tests a new drug, DS1025a, for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if it is safe and how well it works.

Kashiwa
NCT06245122Recruiting· Phase 1
Study of CS23546 for advanced tumors

This trial tests a new drug called CS23546 for people with advanced solid tumors or lymphoma that have not responded to other treatments. Researchers will check your tumor for certain markers (PD-L1 and MSI) to see if the drug might work for you.

Guangzhou
NCT07739966Not yet recruiting· Phase 1/Phase 2
Study of DS-3939a for advanced solid tumors

This trial tests a new drug called DS-3939a for people with advanced solid tumors, especially a type of lung cancer. The drug targets a protein on cancer cells to try to shrink tumors or slow their growth.

NCT07182591Recruiting· Phase 1
Study of DS5361b for advanced solid tumors with high TMB or MSI

This study tests a new drug (DS5361b) for people with advanced solid tumors that have high genetic instability (TMB-H or MSI-H). It aims to see if the drug can shrink tumors or slow their growth.

Sarasota, Florida
NCT05875168Recruiting· Phase 1/Phase 2
Study of DS-3939a for Advanced Solid Tumors

This trial is testing a new drug called DS-3939a for people with advanced solid tumors that have not responded to other treatments. The study has two parts to find the right dose and see how well it works.

Sarasota, Florida

Hear when a new Sarcoma trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.